Background and Aim: The treatment of choice for relapsed or refractory Non-Hodgkin Lymphoma (NHL) mainly, is High dose chemotherapy with autologous stem cell transplantation. However, its use is mostly restricted to patients responding to salvage chemotherapy. In this study, our aim was to evaluate outcome and toxicity of different treatment modalities of relapsed and refractory NHL. Patient and Methods: This retrospective study included 217 patients were diagnosed as refractory or relapsed NHL. Those patients received different treatment modalities as GDP (Gemcitabine, dexamethasone, cisplatin), DHAP (Dexamethasone, Cytarabine, and Cisplatin), MINE (Mitoxantrone, ifosfamide, etoposide and mesna), CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), and CVP (Cyclophosphamide, vincristine and prednisone). Results: The median age of patients in the study was 50 years. Patients who received DHAP showed ORR of 62%, which was the highest response. The most common adverse effects were hematological which were more noticed in patients, received CHOP. Sixty one patients (54.5%) had anemia, 54 patients (48.2%) had neutropenia and 55 patients (49.1%) had thrombocytopenia, but th e difference between the different lines of treatment wasn’t significant p value of 0.95. The median time to relapse is 10 months and the median survival time is 40 months. The 3-year PFS rates of all patients were 49.3%, while the 3 year OS rates were 54.8%. Conclusion: The overall and PFS didn’t show any difference betwee n different lines of treatment.
Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254
Shustik, J., Quinn, M., Connors, J.M., Gascoyne, R.D., Skinnider, B. and Sehn, L.H. (2011) Follicular Non-Hodgkin Lymphoma Grades 3A and 3B Have a Similar Outcome and Appear Incurable with Anthracycline-Based Therapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 22, 1164-1169. https://doi.org/10.1093/annonc/mdq574
Tan, D., Horning, S.J., Hoppe, R.T., Levy, R., Rosenberg, S.A., Sigal, B.M., et al. (2013) Improvements in Observed and Relative Survival in Follicular Grade 1-2 Lymphoma during 4 Decades: The Stanford University Experience. Blood, 122, 981-987. https://doi.org/10.1182/blood-2013-03-491514
Zhang, Q.Y. and Foucar, K. (2009) Bone Marrow Involvement by Hodgkin and Non-Hodgkin Lymphomas. Hematology/Oncology Clinics of North America, 23, 873-902. https://doi.org/10.1016/j.hoc.2009.04.014
Witzig, T.E., Nowakowski, G.S., Habermann, T.M., Goy, A., Hernandez-Ilizaliturri, F.J., Chiappella, A., et al. (2015) A Comprehensive Review of Lenalidomide Therapy for B-Cell Non-Hodgkin Lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 26, 1667-1677. https://doi.org/10.1093/annonc/mdv102
Seshadri, T., Kuruvilla, J., Crump, M. and Keating, A. (2008) Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 14, 259-267. https://doi.org/10.1016/j.bbmt.2007.11.013
Moccia, A.A., Hitz, F., Hoskins, P., Klasa, R., Power, M.M., Savage, K.J., et al. (2017) Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is an Effective and Well-Tolerated Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma. Leukemia & Lymphoma, 58, 324-332. https://doi.org/10.1080/10428194.2016.1193852
Magnano, L., Balague, O., Dlouhy, I., Rovira, J., Karube, K., Pinyol, M., et al. (2017) Clinicobiological Features and Prognostic Impact of Diffuse Large B-Cell Lymphoma Component in the Outcome of Patients with Previously Untreated Follicular Lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28, 2799-2805. https://doi.org/10.1093/annonc/mdx407
Park, B.B., Kim, W.S., Suh, C., Shin, D.Y., Kim, J.A., Kim, H.G., et al. (2015) Salvage Chemotherapy of Gemcitabine, Dexamethasone, and Cisplatin GDP for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: A Consortium for Improving Survival of Lymphoma (CISL) Trial. Annals of Hematology, 94, 1845-1851. https://doi.org/10.1007/s00277-015-2468-y
Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., et al. (1989) Report of a Committee Convened to Discuss the Evaluation and Staging of Patients with Hodgkin’s Disease: Cotswolds Meeting. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 7, 1630-1636. https://doi.org/10.1200/JCO.1989.7.11.1630
Kaplan, E.L. and Meier, P. (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457-481. https://doi.org/10.1080/01621459.1958.10501452
Gangatharan, S. and Kuruvilla, J. (2013) Relapsed and Refractory Aggressive NHL: Time for a Change. Transfusion and Apheresis Science, 49, 72-79. https://doi.org/10.1016/j.transci.2013.05.029
Rybka, J., Jurczak, W., Giza, A., Paszkiewicz-Kozik, E., Kumiega, B., Drozd-Sokolowska, J., et al. (2015) Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma Multicenter Polish Experience. Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University, 24, 783-789. https://doi.org/10.17219/acem/34795
RaniaHafez, S. and Ismail, M. (2018) Definitive Salvage Chemotherapy for the Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma, a Single Center Experience. Alexandria Journal of Medicine, 54, 679-683. https://doi.org/10.1016/j.ajme.2018.07.006
Ismail, S.A., Han, R., Sanborn, S.L., Stevens, S.R., Cooper, K.D., Wood, G.S., et al. (2007) Immunohistochemical Staining for CD45R Isoforms in Paraffin Sections to Diagnose Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma. Journal of the American Academy of Dermatology, 56, 635-642. https://doi.org/10.1016/j.jaad.2006.08.069
Abali, H., Urun, Y., Oksuzoglu, B., Budakoglu, B., Yildirim, N., Guler, T., et al. (2008) Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma. Cancer Investigation, 26, 401-406. https://doi.org/10.1080/07357900701788098
Sweetenham, J., Hieke, K., Kerrigan, M., Howard, P., Smartt, P.F., McIntyre, A.M., et al. (1999) Cost-Minimization Analysis of CHOP, Fludarabine and Rituximab for the Treatment of Relapsed Indolent B-Cell Non-Hodgkin’s Lymphoma in the UK. British Journal of Haematology, 106, 47-54. https://doi.org/10.1046/j.1365-2141.1999.01515.x
Crump, M., Kuruvilla, J., Couban, S., MacDonald, D.A., Kukreti, V., Kouroukis, C.T., et al. (2014) Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 32, 3490-3496. https://doi.org/10.1200/JCO.2013.53.9593
Park, B.B., Kim, W.S., Eom, H.S., Kim, J.S., Lee, Y.Y., Oh, S.J., et al. (2011) Salvage Therapy with Gemcitabine, Ifosfamide, Dexamethasone, and Oxaliplatin (GIDOX) for B-Cell Non-Hodgkin’s Lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) Trial. Investigational New Drugs, 29, 154-160. https://doi.org/10.1007/s10637-009-9320-y
Li, Y.H., Jiang, W.Q., Huang, H.Q., Zhang, L., Liu, D.G., Xu, R.H., et al. (2002) Preliminary Study on DHAP Regimen for Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma. Chinese Journal of Cancer, 21, 900-902.
Fan, Y., Huang, Z.Y., Luo, L.H. and Yu, H.F. (2008) Efficacy of GDP Regimen (Gemcitabine, Dexamethasone, and Cisplatin) on Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma: A Report of 24 Cases. Chinese Journal of Cancer, 27, 1222-1225.
Wang, J.J., Dong, M., He, X.-H., Li, Y.-X. and Wang, W.-H. (2016) GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Hochster, H., Weller, E., Gascoyne, R.D., Habermann, T.M., Gordon, L.I., Ryan, T., et al. (2009) Maintenance Rituximab after Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 1607-1614. https://doi.org/10.1200/JCO.2008.17.1561